Driven by Industry Demand, Georgia Bio Reemerges, Rededicates

Georgia Bio logo with tagline

A New Start

Founded in 1989, Georgia Bio has been the entity around which the bioscience and medtech industry in the state, including academia, connects and advocates for its needs.

Though recently latent in the visual presence to which stakeholders are accustomed, Georgia Bio has maintained, if not increased, its advocacy for the life science industry at the state level. Over the past two years, Georgia Bio operated under the moniker “Office of Life Sciences and Digital Health” within the Center for Global Health Innovation (CGHI). Given CGHI’s changing scope, Georgia Bio reemerges as a 501c6 trade organization serving its member stakeholders directly inclusive of advocacy and lobbying activities. Georgia Bio has finalized the steps needed to regain its full autonomy and independence from CGHI.

“The ‘re-emergence’ of Georgia Bio is an industry demand-driven development,” Georgia Bio CEO Maria Thacker says. “Academic and industry life science leaders have told us directly that they need a strong advocacy organization around which to engage with each other and advance their priorities. Those industry leaders are also prepared to provide the financial support required for Georgia Bio to be the entity that provides those services.”

Not Just Pharma: A Holistic View of the Life Sciences

Known most for its focus in the biotech and pharmaceutical sectors of the life sciences, Georgia Bio intends to bring the breadth of the life science innovation ecosystem into its “family” inclusive of medical devices, food and agricultural technology and the solutions providers that support them. The increasing number of ‘combination devices,’ medical technologies that are part drug, part device in simplest terms, is one of the easiest ways to understand why the expansion of focus is needed. The affiliated solution providers on which the entire industry relies, including intellectual property experts, contract manufacturers and proving grounds like the Global Center for Medical Innovation is another.

“Ultimately, we intend to foster innovation and growth of Georgia’s life science ecosystem for a healthier world,” Thacker says. “We will advocate for, connect, educate and inspire our member enterprises and stakeholders in much the same way our colleagues have known Georgia Bio since its inception in 1989. We will now do that through an industry-wide lens including new medical technologies and devices.”

Supporting an Industry with $50 Billion Impact and High Workforce Development Needs

A top priority for the organization in addition to advocacy will be continued strengthening of its workforce development programming.

The 2022 Georgia Life Sciences Industry Trends and Impacts Report states, “Job growth in the industry has been driven primarily by the industrial life sciences segment which has increased by nearly 29% and outpaced the nation, while the academic and federal R&D component has experienced more modest growth. In 2021, Georgia’s life sciences industry and its multiplier effects generated: a total employment impact of nearly 215,000 Georgia workers across all sectors, a combined $50.2 billion in total economic impact to Georgia’s economy, and a total value added impact of $26.7 billion to Georgia’s GSP-representing 3.9% of state GSP.”

The growth of the sector across the state has also increased the need for a skilled workforce to support it. In that regard, the Georgia BioEd Institute will serve as the 501c3 public service entity whose education and workforce development endeavors will be administered by the Georgia Bio team as well. The Institute will operate inside of Georgia Bio with the 501c3 status anticipated to be completed by early 2024.

The 2023 Georgia Life Science Summit

Coming out swinging, Georgia Bio hosted The Georgia Life Science Summit on November 1, 2023 at the Sandy Springs Arts Center.

“The Summit was more concentrated in its focus, yet more expansive in its industry-wide inclusion, compared to previous editions of our Bio Innovation Summit,” Thacker says. “In line with what the industry has told us it wants and needs, the event will bring together roughly 300 academic and industry leaders to connect, learn, share and network.”

For more information, visit www.georgiabiosummit.org.

About Georgia Bio

Georgia Bio represents more than 200 organizations in the life sciences industry, including biopharma, medical device, combination product and digital health companies, along with academic institutions, research hospitals, disease foundations and solutions providers on which those entities rely. www.gabio.org

____________________________________________________________________

By Maria Thacker Goethe April 18, 2025
The Science & Community Impacts Mapping Project (SCIMaP) shows how proposed federal funding cuts lead to reduced economic activity and job losses nationwide.
By Sheran Brown April 10, 2025
Georgia Life Sciences Selects Fulton County Schools Innovation Academy Student as the 2025 Georgia BioGENEius Winner Sandy Springs & Rockmart Teens Take Top Honors in Statewide Science Competition Atlanta, GA (April 4, 2025) – Georgia Life Sciences today named Bhavya Alapati , a junior at Fulton County Schools Innovation Academy, as the winner of the 2025 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. Eleven students from across Georgia competed for this year’s title and cash prize. Bhavya’s project investigated a novel method of identifying strokes using a device she created called SpectroStroke, a small-scale spectrophotometer, to detect homocysteine, an amino acid product that is associated with stroke. Bhavya identified the ability of homocysteine to be detected using Ellman’s reagent, which reacts with the free sulfhydryl group on the molecule to produce a yellow color. Bhavya created a wearable patch that contains the Ellman’s reagent. Then, she designed the SpectroStroke to be able to detect the color change when the patch is exposed to elevated levels of homocysteine. Bhavya’s SpectroStroke can detect normal levels of homocysteine up to extremely high levels seen in those experiencing a stroke. The ability to detect a stroke earlier would reduce damage and long-term effects of the condition. A future iteration of the SpectroStroke would include real-time monitoring capabilities to help track changing homocysteine levels. "Supporting and celebrating outstanding research and innovation in biotechnology is vital for the future of science and medicine. The Georgia BioGENEius Challenge not only encourages the brightest young minds to explore their potential but also nurtures the next generation of leaders who will drive groundbreaking advancements in biotechnology,” said Georgia Life Sciences President and CEO Maria Thacker-Goethe. “By recognizing and empowering these students, we are helping to shape a future where innovation thrives and the possibilities for improving lives are endless. Well done, Bhavya!” Georgia Life Sciences also congratulates the Georgia BioGENEius runner-up, Shelby Kendrick , who is a senior at Paulding County High School in Dallas, GA. Shelby’s research investigated the ability of Aspergillus terreus, a fungus found in soil, to degrade pre-treated polypropylene plastic (PP). This fungus has been discovered to produce high concentrations of degrading enzymes and raises the moisture level of its substrate. Shelby isolated the fungus from soil samples and confirmed the species using PCR amplification and DNA barcoding. Samples of polypropylene were pre-treated with 75% ethanol and UV exposure, then placed in a liquid culture of A. terreus in Minimal Salt Medium (MSM) media, and the culture was incubated for 23 days. At the end of the trial period, PP samples were analyzed using Scanning Electron Microscopy. These samples showed changes in their surface layer, indicating evidence of biodegradation. Polypropylene plastic is found in household items such as plastic cups and is a known problem in the environment due to its inability to degrade. Shelby’s future research on the use of A. terreus for biodegradation includes optimizing degradation conditions and assessing methods of application in the environment. Judging the 2025 Georgia BioGENEius Challenge were Ralph L. Cordell, CDC, and Alex Harvey, ViaMune. Cash prizes were awarded to Bhavya and Shelby. # # # About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
By Maria Thacker Goethe April 9, 2025
Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition
MORE POSTS